Related Experiment Videos
[Therapeutic problems in hyperkinetic heart syndrome]
Insights
Beta-blockers safely reduce heart rate in hyperkinetic heart syndrome but do not sufficiently lower blood pressure. Verapamil offers better hypotensive effects, suggesting it as a potential alternative therapy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hyperkinetic heart syndrome is typically treated with beta-blockers.
- The efficacy of current beta-blocker therapy in managing blood pressure in this condition requires further investigation.
Purpose of the Study:
- To compare the circulatory effects of specific beta-blockers (Celiprolol, Pindolol, Oxprenolol) with each other and with the calcium antagonist Verapamil in hyperkinetic heart syndrome.
- To evaluate the effectiveness of these agents in reducing heart rate and diastolic blood pressure.
Main Methods:
- Two crossover studies were conducted.
- Study 1: Celiprolol vs. Pindolol.
- Study 2: Oxprenolol vs. Verapamil.
Main Results:
- All tested beta-blockers effectively reduced elevated heart rate.
- Beta-blockers failed to achieve a significant reduction (≥15 mm Hg) in diastolic blood pressure.
- Verapamil also caused bradycardia but had less impact on heart rate compared to beta-blockers.
- Verapamil demonstrated more pronounced hypotensive effects than beta-blockers.
Conclusions:
- Beta-blockers may not be the first-line therapy for hyperkinetic heart syndrome due to insufficient blood pressure reduction.
- Beta-blockers might be effective when combined with diuretics or vasodilators.
- Verapamil presents a viable alternative therapy, despite requiring multiple daily doses.
Abstract:
At present beta-blockers are the therapy recommended in hyperkinetic heart syndrome. This therapeutical advice was investigated by two cross over studies: the first trial was a comparison between the circulatory effects of Celiprolol and Pindolol, the second one between Oxprenolol and the calcium antagonist Verapamil. All beta-blockers tested effected a safe reduction in heart rate, which is elevated in hyperkinetic state, but failed to lower diastolic blood pressure by at least 15 mm Hg. Verapamil however, also effected bradycardia but did not reduce heart-rate in the same amount as beta-blockers. Furthermore the calcium antagonist's hypotensive effects are more pronounced by comparison with beta-blockers. According to these findings beta-blockers are not to be seen as therapy of first choice in hyperkinetic heart syndrome, they are only recommended combined with diuretics or vasodilators. As alternative therapy Verapamil could be prescribed, which disadvantage is the necessity of taking it several times per day.